Research & Development
In 2016, Eisai’s medium-term business plan positioned neurological diseases and cancer as strategically important areas, where patients’ true needs remained unmet, and where Eisai could be a front runner.
As a result, the Neurology Business Group (NBG) and the Oncology Business Group (OBG) were established. These two organisational structures bring together all integrated business functions, from research and development, through to sales. These groups carry out research and development for approved opportunities in these two highlighted areas.